CRUK CI, credit Phil Mynott

Cancer Research UK Cambridge Institute

The Cancer Research UK Cambridge Institute aims to bring the scientific strengths of Cambridge to bear on practical questions of cancer diagnosis, treatment and prevention. The Institute focuses specifically on the practical application of high-quality basic research.

About us

Latest news

  • News

    New findings in ER+ breast cancer

    Researchers at the Institute have discovered that estrogen-dependent gene expression in breast tumour cells is not cyclical, as previous studies have suggested. Breast cancer is the most common form of cancer, and in 70% of cases tumour growth is driven by the hormone estrogen.  This form of breast cancer is called estrogen receptor positive (ER+) […]

    Find out more
  • News

    Cancer Research UK and AstraZeneca launch world class functional genomics centre

    Cancer Research UK and AstraZeneca have announced today (Monday) that they are opening a new centre in Cambridge, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer. This partnership will explore in more detail the function and interaction of genes and proteins in […]

    Find out more
  • News

    AI system may accelerate search for cancer discoveries

    Searching through the mountains of published cancer research could be made easier for scientists, thanks to a new AI system. The system, called LION LBD and developed by computer scientists and cancer researchers at the University of Cambridge, has been designed to assist scientists in the search for cancer-related discoveries. It is the first literature-based […]

    Find out more
  • News

    Pancreatic cancer pioneers awarded £200K for ‘barcode’ cancer tech

    As pancreatic cancer awareness month gets underway, scientists at the Cancer Research UK Cambridge Institute are aiming to develop an innovative cancer ‘barcoding’ technology that could unlock the secrets of the disease. Pancreatic cancer is one of the hardest to treat and advances are desperately needed as only one per cent of patients survive for […]

    Find out more

Who we work with